# New York Approves Medical Cannabis for Anxiety Despite Limited Evidence > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-anxiety-policy-new-york-approval-evidence/ > **Published:** 2026-04-07T10:04:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:25-04:00 > **Clinical Summary:** Explore New York's medical cannabis anxiety policy and the clinical evidence gaps surrounding cannabis use for anxiety disorders. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AnxietyMedical Cannabis PolicyThcCbdMental Health Why This Matters New York’s addition of anxiety to its medical cannabis program creates a disconnect between policy and clinical evidence. This expansion affects how clinicians counsel patients about cannabis for anxiety disorders and highlights the need for evidence-based prescribing guidance. Clinical Summary New York has approved anxiety as a qualifying condition for medical cannabis, despite limited clinical evidence supporting cannabis efficacy for anxiety disorders. While some patients report subjective anxiety relief with cannabis use, controlled studies show mixed results, with THC potentially exacerbating anxiety in some individuals and CBD showing modest benefits in specific anxiety disorders. The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) does interact with anxiety pathways, but therapeutic ratios and optimal formulations remain poorly defined. Dr. Caplan’s Take “I see patients daily who believe cannabis will cure their anxiety, but the science isn’t there yet. We’re making policy decisions ahead of our clinical understanding, which puts both patients and providers in difficult positions.” Clinical Perspective 🧠 Clinicians should counsel patients that cannabis for anxiety lacks robust clinical validation and may worsen symptoms in some cases. Consider starting with evidence-based anxiety treatments first, and if patients pursue cannabis, monitor closely for both therapeutic response and potential anxiety exacerbation, particularly with THC-dominant products. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20York%20approves%20cannabis%20for%20anxiety.%20Science%20says%20it%20may%20not%20help%20-%20MSN%20-%20CED...%20%40drcaplan&url=https%3A//cedclinic.com/new-york-approves-cannabis-for-anxiety-science-says-it-may-not-help-msn-2/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//cedclinic.com/new-york-approves-cannabis-for-anxiety-science-says-it-may-not-help-msn-2/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20York%20approves%20cannabis%20for%20anxiety.%20Science%20says%20it%20may%20not%20help%20-%20MSN%20-%20CED...%20--%20via%20%40drcaplan.bsky.social%20https%3A//cedclinic.com/new-york-approves-cannabis-for-anxiety-science-says-it-may-not-help-msn-2/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://cedclinic.com/new-york-approves-cannabis-for-anxiety-science-says-it-may-not-help-msn-2/](https://cedclinic.com/cannabis-for-anxiety-disorders-evidence-policy/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What medical conditions does this cannabis research focus on?](#What_medical_conditions_does_this_cannabis_research_focus_on) - [Which cannabis compounds are discussed in this article?](#Which_cannabis_compounds_are_discussed_in_this_article) - [Is this article related to medical cannabis policy changes?](#Is_this_article_related_to_medical_cannabis_policy_changes) - [Who is the target audience for this clinical cannabis information?](#Who_is_the_target_audience_for_this_clinical_cannabis_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the findings or policy developments are considered emerging and worth monitoring closely by healthcare professionals. #### What medical conditions does this cannabis research focus on? Based on the tags, this research appears to focus primarily on anxiety disorders. The article examines how medical cannabis may be used as a treatment option for anxiety-related conditions. #### Which cannabis compounds are discussed in this article? The article covers both THC and CBD, the two primary cannabinoids in medical cannabis. These compounds have different therapeutic properties and effects on anxiety symptoms. #### Is this article related to medical cannabis policy changes? Yes, the article includes medical cannabis policy as a key topic area. This suggests it may discuss regulatory developments or policy changes affecting medical cannabis access for anxiety treatment. #### Who is the target audience for this clinical cannabis information? This information is published by CED Clinic and appears to target healthcare professionals and clinicians. The clinical relevance rating system suggests it’s designed to help medical practitioners stay informed about emerging [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and policy developments. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Is Cannabis Effective for Treating Mental Health Disorders? – Labroots](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) An in-depth look at the current research on cannabis efficacy for mental health conditions including anxiety. [Read More](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) New Studies Illuminate Health Effects of Cannabis Use – NUG Magazine Recent studies shed light on the health impacts of cannabis, relevant for anxiety and other disorders. Explore Studies [The Evolving Science of Cannabis Medicine](https://cedclinic.com/the-evolving-science-of-cannabis-medicine/) A comprehensive overview of advances in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), including policy and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) updates. [Learn More](https://cedclinic.com/the-evolving-science-of-cannabis-medicine/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).